

---

## SARS-CoV-2 (2019-nCoV) Spike Neutralizing Mouse mAb

Catalog Number: bsm-41635M

Target Protein: SARS-CoV-2 (2019-nCoV) Spike Neutralizing

Concentration: Lot Dependent

Form: Size : 100ug

Liquid

Size : 200ug (PBS only)

Lyophilized

Note: Centrifuge tubes before opening. Reconstitute the lyophilized product in distilled water. Optimal concentration should be determined by the end user.

Host: Mouse

Clonality: Monoclonal

Clone No.: 7A7

Isotype: IgG1

Applications: ELISA (1:5000-10000)

Reactivity: SARS-CoV-2

Predicted MW: 140 kDa

Source: Recombinant SARS-CoV-2 Spike S1 Protein: 14-685/1213.

Purification: affinity purified by Protein A

Storage: Size : 100ug

0.01M PBS (pH7.4).

Size : 200ug (PBS only)


0.01M PBS

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.


**Background:** The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.

### VALIDATION IMAGES

---



Direct ELISA was used to detect the binding ability of anti-RBD monoclonal antibody to RBD domain proteins of different SARS-CoV-2 Mutant Strains. Immobilized SARS-CoV-2 RBD proteins, at 2µg/ml (100ul/Well) can bind Anti-RBD monoclonal antibody-HRP at 1ug/ml (100ul/Well).



The ACE2-coated plate is incubated with SARS-CoV-2 Spike RBD-HRP (WT) and Anti-SARS-CoV-2 Spike RBD Neutralizing antibody. Percent inhibition is calculated based on the OD value by inhibiting RBD: ACE2 interaction.